press-releases

Feb 04, 2025, 07:30 ET CUPERTINO, Calif., Feb. 4, 2025 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, to be held virtually, February 11-12, 2025. Presentation details are as follows: Date and time:         Tue, Feb […]

Jan 28, 2025, 10:09 ET The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company’s planned Phase 3 trial CUPERTINO, Calif., Jan. 28, 2025 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM

Nov 25, 2024, 06:00 ET CUPERTINO, Calif., Nov. 25, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET® line of osmotic pumps to Lafayette Instrument Co.

Nov 13, 2024, 16:01 ET –     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation –     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the

Nov 06, 2024, 16:45 ET CUPERTINO, Calif., Nov. 6, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13,

Oct 17, 2024, 08:30 ET CUPERTINO, Calif., Oct. 17, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver

Sep 25, 2024, 08:00 ET – Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design – Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation  – Protocol for Phase 3

Sep 04, 2024, 16:30 ET CUPERTINO, Calif., Sept. 4, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management’s participation in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 16:01 ET –         FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis –         Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design –         Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 –         Webcast of Earnings Call

Aug 07, 2024, 16:30 ET CUPERTINO, Calif., Aug. 7, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August